To determine the prevalence and extent of autonomic neuropathy amongst Africans with insulin-dependent diabetes mellitus (IDDM), we investigated 50 such patients at our clinic. Mean age (± 1 s.d.) was 26± 6 years, male:female ratio was equal (25M:25F) and duration of diabetes was 4.0 ± 3.0 years. A battery of six validated tests of autonomic function was performed, testing both sympathetic and parasympathetic systems. Overall 16 (32%) had evidence of autonomic damage, affecting parasympathetic only in 14, and both sympathetic and parasympathetic in two. Those with autonomic neuropathy had a significantly longer diabetes duration than those without (6.0± 2.8 years versus 3.1 ± 2.7 years, P<0.005), but there was no difference in glycosylated haemoglobin (HbAj) between the two groups.
Introduction
Autonomic neuropathy is an unusual but important manifestation of diabetic complications. Its importance has only been appreciated since effective clinical tests of cardiovascular responses to autonomic stimuli have been described.' Using such criteria it has been demonstrated that autonomic neuropathy affects some 20-40% of the diabetic population,2,3 the parasympathetic system being involved first and the sympathetic later. 4 Classical symptoms of autonomic neuropathy such as diarrhoea, vomiting, bladder dysfunction, postural dizziness and impotence, are clearly important, but they are relatively rare, and are also non-specific and poor indicators of overall autonomic neuropathy prevalence.3'4 One exception appears to be gustatory sweating, which seems quite specific to diabetes.5 Of great importance is the observation that the presence of autonomic neuropathy greatly worsens the prognosis of diabetes: the follow-up study by Ewing and colleagues6 suggested a 50% mortality risk at 5 years from diagnosis.
There is little information in the literature on autonomic neuropathy in Black African diabetes, apart from single reports on South African7 and Zambian' patients. The Table III ). Four (8%) had borderline tests and in 30 (60%) the tests were normal. There is a known relationship between peripheral and autonomic neuropathy,16"7 some suggesting that peripheral nerve dysfunction is present in all cases of autonomic neuropathy. '8 Overall 87% of our group with autonomic neuropathy had associated peripheral neuropathy, but the figure for those without autonomic neuropathy was also high at 71% and the difference was not significant. Because of the higher overall prevalence of peripheral neuropathy (76%), we would presumably require larger numbers to demonstrate an association. Similarly our prevalence of retinopathy was too small to allow us to attempt correlation with autonomic neuropathy.
As has been mentioned, symptoms ofautonomic neuropathy are non-specific,3'4 and our results confirm this with suggestive symptoms present in only 41% of patients with autonomic neuropathy and also in 38% of those without. The actual cause of diabetic neuropathy is still unknown, but it is widely thought to be related to prolonged poor glycaemic control and frequently ameliorates with improved control.'9'20 Such studies, however, are concerned with peripheral rather than autonomic neuropathy. The latter does not often improve or resolve in the same way as peripheral neuropathy6 and may possibly be due to different underlying processes. In this context it is of interest that overall glycaemic control, as measured by current HbAj levels, was similar in those with and without autonomic neuropathy in our series. A recent Swedish study,2' and particularly the American DCCT study22 have confirmed the strong association of glycaemic control with complication risk in IDDM. In the latter study,22 autonomic function tests were performed and the risk of development of autonomic neuropathy was reduced in the cohort with intensified glycaemic control.
The autonomic function tests we used are not technically difficult to perform, though the full battery of five tests is relatively time-consuming. Nevertheless, there is no doubt that to properly assess the prevalence of autonomic neuropathy, this type of screening has to be performed. Our prevalence of 32% in young Sowetan IDDM patients, at an average duration of only 6 years, is of considerable concern, particularly in view of the gloomy prognosis of autonomic neuropathy, with over half dying at 5 years from diagnosis.
